Cutaneous angiosarcoma: A review of current evidence for treatment with checkpoint inhibitors
Cutaneous angiosarcoma (cAS) is a rare and aggressive subtype of soft tissue sarcoma with poor prognosis and suboptimal treatment options. Clinical presentation is variable, but cAS often arises from the head and neck. The most widely accepted current approach, surgical excision with adjuvant radiot...
Main Authors: | Lucy Guan, Marisa Palmeri, Roman Groisberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1090168/full |
Similar Items
-
PD-L1 Expression in Cutaneous Angiosarcomas: A Systematic Review with Meta-Analysis
by: Renato Lobrano, et al.
Published: (2023-05-01) -
Advances in immune checkpoint inhibitors for hepatocellular carcinoma
by: Ji Won Han, et al.
Published: (2021-09-01) -
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy
by: Jan Willem Kleinovink, et al.
Published: (2017-04-01) -
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
by: Vida Vafaizadeh, et al.
Published: (2020-03-01) -
Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
by: Zachary S. Buchwald, et al.
Published: (2018-12-01)